DYRUPEG Trademark

Medicinal preparations for use in reducing the duration and incidence of neutropenia and febrile neutropenia, reducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils, and stimulating white blood cell production; Pharmaceutical preparations for use in reducing the duration and incidence of neutropenia and febrile neutropenia, reducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils, and stimulating white blood cell production; Pharmaceutical preparations for use in reducing the duration and incidence of neutropenia and febrile neutropenia, reducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils, and stimulating white blood cell production, namely, in the form of injectable pharmaceutical solutions; Pharmaceutical preparations for use in reducing the duration and incidence of neutropenia and febrile neutropenia, reducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils, and stimulating white blood cell production, namely, in the form of biopharmaceutical preparations; Pharmaceutical preparations for use in reducing the duration and incidence of neutropenia and febrile neutropenia, reducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils, and stimulating white blood cell production, namely, in the form of biopharmaceutical preparations and substances, namely, polypeptides, proteins, and monoclonal antibodies